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Abstract
Background: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We
previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a
cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and
eliminate tumor in vivo.
Methods: In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of
cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis
virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles
of the cell lines prior infection.
Results: We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The
heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also
tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant
correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be
identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis
permissivity to viral infection.
Conclusions: Our findings have implications for the design of oncolytic therapies for cancer and offer insights into
the nature of permissivity of tumor cells to viral infection.
Background
Despite improvements in conventional cancer treatment
the prevalence of cancer-related deaths has minimally
changed and novel therapeutic strategies are continu-
ously sought. Among them, replication competent onco-
lytic viruses are increasingly studied because of their
intrinsic tumor tropism [1]. This tropism for cancer
cells is engineered by the disruption of non-essential
viral genes altering their replicative capacity in a tissue-
specific fashion [2-4].
Their selective intra-tumoral replication leads to kill-
ing of infected cancer cells by virus-specific and
apoptosis-independent mechanisms (oncolysis) [5] or
through activation of anti-viral immune mechanisms
that clear tumors cells infected with virus [6].
Among poxviruses, Vaccinia Virus (VACV) is a pro-
mising candidate for oncolytic therapy due to its exten-
sive past utilization for worldwide vaccination against
smallpox that demonstrated its safety in humans.
Although VACV is known to infect a variety of mam-
malian cell lines, recent evidence highlights the impor-
tance of host restriction in infection permissivity. Genes
known to influence the ability of VACV to infect cells,
termed host range genes, have been identified, and
hypothesized to block productive infection at different
points in the replication cycle [7,8]. In addition to host
genes, a number of other factors might influence the
permissivity to infection of a given cell type, such as its
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any medium, provided the original work is properly cited.tissue accessibility in vivo, the special vascular structure
of tumor, the density of cellular receptors for the virus,
the ability to internalize the virus, the metabolic state of
the cell and intrinsic genetic differences within each
viral species [8]. Thus, we hypothesized that, although
receptors for VACV are believed to be ubiquitous, and
VACV replication is relatively independent from the
host cell, virus tropism may be determined by other
subtle factors that may be dependent upon the cell type
and its metabolic state; the same factors may affect the
efficiency of replication in different cancers in vitro and/
or in vivo.
Recently, Zhang et al introduced GLV-1h68 as a
recombinant VACV derived from LIVP wild-type strain
by insertion of three expression cassettes encoding
Renilla luciferase-Aequorea green fluorescent protein
fusion (Ruc-GFP), beta-galactosidase (b-gal) and beta-
glucuronidase (b-glu) into the F14.5L, J2R (encoding
thymidine kinase) and A56R (encoding haemagglutinin)
respectively [7]. The ability to replicate exclusively
within tumors while completely sparing non malignant
tissues, makes GLV-1h68 systemic administration a pro-
mising tool capable of safely eradicating pancreatic can-
cer malignant pleural mesothelioma [9], breast
carcinoma [7], anaplastic thyroid cancer [10] and squa-
mous cell carcinoma xenografts [11]. In a xenograft
model, we recently observed a correlation between the
cell line-specific ability of GLV-1h68 to replicate in vitro
in the first 20 hours of infection and its effectiveness in
vivo in colonizing and causing regression of the corre-
sponding tumor implants [12]. Thus, we screened a
panel of cell lines, often used as a standard for the study
of cancer therapeutics, for their permissivity to VACV
infection/replication in vitro. Our final intent was devel-
oping a roadmap for the design and interpretation of
future studies adopting viral oncolytic strategies. We
screened the NCI-60 panel constituted by cancer cell
lines of diverse lineage derived from nine distinct tissues
(breast, colon, central nervous system, renal, lung, mela-
noma, ovarian, prostate, and blood) previously charac-
terized extensively by the National Cancer Institute
[13-17]. In addition, we screened 15 cell lines that we
previously characterized for their in vitro permissivity to
GLV-1h68 replication as well as in vivo responsiveness
to GLV-1h68 oncolytic effects [12]. Infection with other
non-receptor dependent viruses such as Vesicular Sto-
matitis Virus (VSV) and wild-type strain Western
Reserve (WR) Vaccinia Virus were performed on several
cell lines to test whether information obtained studying
GLV-1h68 could be generalized to other viral con-
structs. All cell lines were grown and tested in identical
conditions and their transcriptional patterns before
infection (as a predictor of permissivity to infection)
were compared. We observed that permissivity to
VACV replication in the first 20 hours following infec-
tion is heterogeneous among cell lines but highly repro-
ducible within each cell line. The tissue of origin of
each cell line does not influence permissivity to infec-
tion with the exception of B cell lymphomas. Permissiv-
ity was similar between two independent VACV
constructs and between them and VSV suggesting that a
general characteristic of the cancer cell may be a com-
mon determinant for the replication of these viruses.
Finally, although a single transcriptional signature pre-
dictive of cell line permissivity was not identified, several
associations were found suggesting a multifactorial con-
trol of viral replication in this model system.
Methods
Cancer cell lines
Fifty-nine available cell lines from the NCI-60 panel
were purchased from NCI-Frederick Cancer Center
DCTD Tumor/Cell Repository. GI-101A cells were
kindly provided by Dr. A. Aller, Rumbaugh-Goodwin
Institute for Cancer Research, Inc., Plantation, Florida
and Huh7.5.1 by Dr. Richard Wang, Department of
Transfusion Medicine, NIH, Bethesda, MD. Three auto-
logous melanoma cell lines (888-MEL, 1858-MEL and
1936-MEL) from temporally distinct cutaneous metas-
tases were derived as previously described [18,19]. MIA-
PaCa2, HT29, A549, OVCAR3, Panc-1, Siha, MDA-MB-
231, NCI-H1299 and PC-3 were purchased from Ameri-
can Type Culture Collection (Manassas) in the past and
have been previously characterized for their in vivo
responsiveness to viral oncolytic therapy with GLV-1h68
by our group [12].
All cells were cultured in Roswell Park Memorial
I n s t i t u t eM e d i u m( R P M I )s u p p l e m e n t e dw i t h1 0 %F B S ,
10 mM HEPES, 1% antibiotic/antimycotic solution. All
cell cultures were carried out at 37°C under 5% CO2.
During prolonged cell culture and immediately before
DNA, RNA isolations and viral infection, all cells were
tested for mycoplasma with the Venor
®GeM Myco-
plasma Detection kit (Sigma, St Louis, MO). In no occa-
sion contamination was detected. Original HLA class I
and II loci sequence-based typing was performed on the
NCI-60 as previously described [20].
Viral constructs and infections
The construction of mutant VACV GLV-1h68 was
described previously [7]. Vaccinia Virus WR-GFP and
VSV-GFP were kindly provided respectively by Drs. N.
Restifo, NCI, Bethesda, MD and S. Balachandran, Fox
Chase Cancer Center, Philadelphia, PA [21]. Before car-
rying out the experimental procedure, cells were thawed
and cultured for three days in RPMI supplemented with
antibiotics. One day following the beginning of culture
cells were harvested for DNA and RNA isolation while a
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Page 2 of 14separate aliquot was exposed to viral infection. For DNA
and RNA isolation, 2 × 10
6 cells were used and 5 × 10
5
cell were used for viral infection.
Cells were infected with VACV GLV-1h68, at multi-
plicity of infection (MOIs) of 0.3 and 0.6 or with Vacci-
nia WR and VSV virus using MOI at 10 and 0.002
respectively. After infection the cells were incubated in
cell culture medium at 37°C for 20 hrs. One hour after
infection the culture media was replaced with fresh
media and cells were incubated at 37°C for 20 hrs.
Quantitative real-time PCR validation of VACV 1h68 gene
expression
Differential expression of viral genes in infected cells
was detected by using TaqMan
® Gene Expression
Assays (Applied Biosystems, Foster City, CA). RNA was
reverse transcribed as above with random oligo primers
in 20 μl final volume. Primer Express 2 (PE2) (Applied
Biosystems, Foster City, CA) was used to generate pri-
mers and a TaqMan probe specific for the virus
sequence; real-time PCR was performed on thermal
cycler 7900HT (Applied Biosystems). Differences in
expression were determined by the ratio of Ct values of
viral genes over those of endogenous control (18s
rRNA).
Plaque forming assay
A375, DU-145 and A549 cell lines were infected with
GLV-1h68 at an MOI of 0.6. At 8, 20 and 36 hours
after infection, tumor cells were harvested and lysates
were prepared by freeze-thawing and sonication in 1 ml
of RPMI media with 10% FBS. The viral titers were
determined by plaque forming assay using TK-cells. TK-
cells (kindly provided by Dr. Jack Bennink, NIAID
Bethesda, MD) were cultured in DMEM media with
10% FBS in 6 well plates. When cell density reached
80%-90% confluence, they were washed with 0.1% BSA
in PBS and infected with 0.5 ml of diluted cell lysate in
PBS with 0.1% BSA for 2 hours at 37°C incubator. Two
ml of cell culture media were then added to each well
and incubated at 37°C and 5% CO2 for 48 hours. Media
were removed from the cells culture and stained with
crystal violet (Sigma, St. Luis, MO) and washed with
PBS. The titer of the virus was determined by the pla-
que numbers of the highest dilution. Each cell lysate
were titered in duplicate.
FACS-analysis of GFP Protein expression
Twenty hours following viral infection, cancer cells were
trypsinized (when applicable), fixed by paraformalde-
hyde, washed with AUTOMacs running buffer and GFP
expression was analyzed with a FACSCalibur flow cyt-
ometer. Data were analyzed by the FlowJo software. To
ensure between-batch reproducibility, all FACS
experiments included BD’s Rainbow Calibration Parti-
cles (6 peaks) as standards and measured signal intensi-
ties were converted in molecules of equivalent
fluorescein, phycoerythrin, or allophycocyanin (MEFL,
MEPE, MEAPC). The flow cytometer settings were kept
constant during the complete experimental procedure
and the cell line A549 was included in all experimental
batches as a positive control for viral infection to asses
inters experimental consistency.
Nucleic acid isolation and preparation
Automated DNA isolation was performed from non-
infected human cancer cell lines using Fujifilm’s Quick-
gen DNA Whole Blood kit and Nucleic Acid Isolation
System-810. Total RNA (tRNA) from tissue cultures was
isolated with the Qiagen miRNeasy Mini kit and its
quality was tested with the Agilent Bioanalyzer 2000
(Agilent Technologies). For expression studies, tRNA
was amplified into antisense RNA (aRNA) as previously
described [22,23]. Reference for human arrays was
obtained by pooling PBMCs from 4 normal donors.
Plaque forming assay on cells cultured with specific
culture media
HT29, Panc 1, NCI-H1299 and A549, cell lines were
simultaneously cultured in four different cell culture
media which were prepared as followed:
Medium 1 (optimized for HT-29 cells)
RPMI 1640 supplemented with 10% FBS and 1% anti-
biotic/antimycotic solution.
Medium 2 (optimized for Panc1)
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% (FBS) and 1% antibiotic/antimycotic
solution.
Medium 3 (optimized for NCI-H1299 cells)
RPMI 1640 supplemented with 10% FBS, 4.5 g/L glu-
cose, 10 mM HEPES, 1 mM sodium pyruvate and 1%
antibiotic/antimycotic solution.
Medium 4 (optimized for A549 cells)
Kaighn’s Modification of Ham’sF - 1 2M e d i u m( F - 1 2 K
Medium) supplemented with 10% FBS and 1% antibio-
tic/antimycotic solution.
Cells lines were infected with GLV-1h68 at an MOI of
0.6. Twenty hours after infection, tumor cells were har-
vested and lysates were prepared by freeze-thawing and
sonication in 1 ml of appropriate media. The viral titers
were determined by plaque forming assay using TK-cells
as above.
Transcriptional analysis
Array quality was documented as previously described
[24]. For 36k human array hybridization, a two color
system was used; both reference and test aRNA were
directly labeled using ULS aRNA Fluorescent Labeling
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with Cy3 for reference and Cy5 for test samples and co-
hybridized to the slides. After 20 h incubation at 42°C
the arrays were washed, dried and scanning using the
Agilent scanner. VACV-gene expression was assessed by
a custom-made VACV array platform (VAC-
GLa520445F, Affymetrix, CA) including 308 probes
representing 219 genes that covered the combined gen-
ome of several VACV strains, the Renilla luciferase-
Aequorea green fluorescent fusion gene specific for
GLV-1h68, and 337 human or mouse “housekeeping”
genes (393 probes) [12]. Five μg tRNA were amplified
using the GeneChip
® One-Cycle Target Labeling and
Control kit (Affymetrix, Santa Clara, CA). After 16 h
incubation in the hybridization oven at 45°C, the arrays
were washed and stained in the Fluidics station using
the GeneChip
® Hybridization, Wash, and Stain Kit
(Affymetrix).
Data processing and statistical analysis
Transcriptional data were uploaded to the mAdb data-
bank (http://nciarray.nci.nih.gov) and further analyzed
using BRBArrayTools developed by the Biometric
Research Branch, NCI (http://linus.nci.nih.gov/BRB-
ArrayTools.html) [25], Partek Genomics Suite (St Louis,
MO) or TreeView software [26]. Gene ratios were aver-
age corrected across experimental samples and displayed
according to uncentered correlation algorithm. Class
comparison was performed using parametric unpaired
Student’s t test or 3-way ANOVA. Adjustments for mul-
tiple test comparisons were based on univariate and
multivariate permutation test. Gene function interpreta-
tion was based on Ingenuity Pathway Analysis (IPA,
Ingenuity Systems). Data ret r i e v e df r o mt h eA f f y m e t r i x
platform was normalized using median over entire array
as reference because of single color labelling technology.
Results and Discussion
Validation of tumor cell lines
T oc o n f i r mc e l ll i n ei d e n t i t ya n de x c l u d ep o s s i b l ec u l -
ture contamination, all cell lines used in this study
were typed for HLA class I which cross referenced to
previous high resolution sequence based typing of
NCI-60 [20] or other cell lines. Among the 74 cell
lines tested, 8 (10.8%) had not been previously geno-
typed, 58 (78.3%) matched previous genotyping results
a n d8( 1 0 . 8 % )d i s p l a y e dad i f f e r e n tg e n o t y p ea n d ,
therefore, their identity could not be verified (Table 1).
In no case more than two alleles per locus were
observed excluding contamination of cultures with
multiple cell lines. Although the identity of 8 cell lines
could not be confirmed, we used their data for this
study because all analyses were performed
contemporarily on the same cell lines and general
information about cell line permissivity and its rela-
tionship with transcriptional data could be compared
directly within each cell line independently of identity.
However, their patterns cannot be extrapolated to
other homonymous cell lines of the same tissue origin
at large because it was impossible to clearly identify and
classify those cell lines.
GFP gene expression correlates with viral transcription
To test whether green fluorescent protein (GFP) expres-
sion by GLV-1h68 correlated with the global transcrip-
tional activity of GLV-1h68 within infected cells, we
hybridized RNA from HT-29 and GI-101A cells infected
with GLV-1h68 at different time points to a customized
whole genome VACV chip and we monitored the
expression of viral genes including Ruc-GFP-fusion.
GFP expression was highly correlated with the expres-
sion of the remaining 219 genes included in the chip. In
particular, GFP expression occurred in the intermediate-
late phase of viral genome expression following the
expression of early-intermediate genes (like Interferon
resistant protein or Interf) and together with other
intermediate-late (IMV surface protein or IMV) genes
(Figure 1A). Moreover, to confirm these finding, we
infected 46 cell lines with GLV-1h68 for 20 hours and
tested the expression of GFP and the two viral non-
structural proteins Interf (or K3L) and IMV (or A27L)
by RT-PCR. A tight correlation was observed between
t h ee x p r e s s i o no fG F Pa n dI n t e r f( R
2 = 0.83) or GFP
and IMV (R
2 = 0.96), (Figure 1B, C). Since the transcrip-
tional expression of GFP is observed in intermediate-late
phase and correlated well with the expression of other
early or late vaccinia genes at the time point studied, we
concluded that GFP is a reliable index of active intra-
cellular virally-driven transcription and, indirectly, repre-
sent a marker of viral replication.
GFP gene expression correlates with viral copy number
estimated by plaque forming assay
To investigate whether GFP positive cells harbor repli-
cating viral particles, we titered the number of plaque
forming unit in lysate of infected cells and correlated
with the expression level of GFP.
A375, DU-145 and A549 cell lines (showing respec-
tively low, intermediate or high GFP by RT-PCR) were
infected with GLV-1h68 for 8, 20 and 36 hours. At the
indicated time points, infected cells were collected and
viral titers were extrapolated in a plaque assay using
TK-cell lines. A375 showed the lowest permissivity to
VACV compared to DU-145 and A549 confirming a
correlation with RT-PCR based estimates of GFP
expression (R
2 = 0.76) (Figure 1D).
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expression
To determine whether the GFP gene transcription cor-
relates with its protein expression, seventy-four cancer
cell lines were infected with GLV-1h68 and GFP expres-
sion was evaluated by FACS analysis. The infection of
the 74 cell lines was performed in batches of five; A549,
evaluated to be highly permissive to GLV-1h68 replica-
tion RT-PCR, was repeatedly used as a positive control
and as cross-reference among different batches. The cell
line demonstrated a highly comparable behaviour in
each batch (data not shown). Since different cell lines
were characterized by different auto-fluorescence, GFP
intensity of uninfected cells was subtracted from GFP
Table 1 HLA class I genotyping results of the 74 cell lines used in the study
Origin Cell line A Locus B Locus Cw Locus Origin Cell line A Locus B Locus Cw Locus
Lung A549 25, 30 18, 44 12, 16 Liver Huh 7.5.1 11 54 1
$ A549 p107 25, 30 18, 44 12, 16 Melanoma *$ 1858-MEL 01, 24 52, 55 01, 12
EKVX 1 37 6 #$ 1936-MEL 3 15/95, 4901 02, 07
HOP 92 03, 24 27, 47 01, 06 397-MEL 01, 25 08, 15/95 04, 07
# HOP62 03, 11 40, 56 01, 03 *$888-MEL 01, 24 52, 55 01, 12
*$ NCI-H1299 24 14 8 *A375 01, 02/92 44, 57 06, 16
NCI-H226 01, 24 07, 39 07, 12 LOX-IMVI 11, 29 07, 44 07, 16
NCI-H23 8001 50 6 M14 11, 24 15/95, 35 03, 04
NCI-H322M 29 44 16 SK-MEL-2 03, 26 35, 38 04, 12
NCI-H460 24, 68 35, 51 03, 15 SK-MEL-28 11 40 3
NCI-H522 02/92 44, 55 03, 05 #SK-MEL-5 02/92, 32 39, 44 05, 12
Cervix *Siha 24 40 3 #UACC-257 01, 32 08, 40 07, 15
CNS SF-268 01, 32 08, 40 02, 07 # UACC-62 02/92, 11 07, 40 03, 07
SF-295 01, 26 07, 55 03, 07 Ovarian IGR-OV1 24, 33 49 7
SF-539 02/92 08, 35 04, 07 NCI/ADR-RES 01, 25 57 6
SNB-19 02/92 18 5 OVCAR-3 02/92, 29 07, 58 7
SNB-75 02/92, 11 35, 39 04, 12 OVCAR-3 p7 02/92, 29 07, 58 7
U251 02/92 18 5 # OVCAR-4 02/92 18, 44 05, 07
Colon COLO 205 01, 02/92 07, 08 7 OVCAR-5 01, 02/92 08, 44 05, 07
HCC 2998 02/92, 24 37, 40 04, 06 OVCAR-8 01, 25 57 6
HCT-116 01, 02/92 18, 45 05, 07 SK-OV-3 03, 68 18, 35 04, 05
HCT-15 02/92, 24 08, 35 04, 07 Pancreas *$ MIA Paca2 24, 32 40, 40 2
HT-29 01, 24 35, 44 4 *$ Panc 1 02/92, 11 38 12
$ HT-29 p155 01, 24 35, 44 4 Renal 786-0 3 07, 44 05, 07
KM12 02/92 7 7 A498 02/92 8 7
SW-620 02/92, 24 07, 15/95 7 ACHN 26 49 7
Breast BT-549 01, 02/92 1517, 55 03, 07 # CAKI-1 02/92, 24 37, 40 04, 06
*$GI-101A 29 07, 08 07, 15 RXF 393 02,24 1444 50,802
# HS-578T 03, 11 40, 56 01, 03 SN12C 03, 24 07, 44 05, 07
MCF-7 02/92 18, 44 5 TK-10 33 14 8
$ MDA-MB-231 p41 02/92 40, 41 02, 17 UO-31 01, 03 07, 14 07, 08
MDA-MB-231 p6 02/92 40, 41 02, 17 Hematopoietic CCRF-CEM 01, 31 08, 40 03, 07
MDA-MB-435 11, 24 15/95, 35 03, 04 HL-60 1 57 6
T-47D 33 14 8 K-562 11, 31 18, 40 03, 05
Prostate $ DU-145 03, 33 50, 57 6 MOLT-4 01, 25 18, 57 06, 12
PC-3 p35 01, 24 13, 55 01, 06 RPMI 8226 30,68 15,15 02.,03
PC-3 p7 01, 24 13, 55 01, 06 SR 02/92, 03 37, 39 06, 12
($) Cell lines previously characterized by our group for their in vivo responsiveness to GLV - 1h68 oncolityc therapies [12].
Among all cells lines, 58 (78.3%) matched previous genotyping results conducted in our lab, 8 (10.8%) had not been previously genotyped (*) and 8 cell lines
(10.8%) displayed a different genotype from our previous genotyping (#) [20].
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observed to vary not only for fluorescence of intensity
(MFI) within the GFP positive cells but also for the per-
centage of fluorescent cells. Therefore for each cell line
we calculated the infectivity index as the product the
two parameters (MFI of GFP and the percentage of
fluorescent cells). Although this index was used for sub-
sequent analyses, either MFI or percent of infection
tightly correlated with the parameter and the salient
conclusions would not change based on the adoption
significantly. We observed a continuous spectrum of
GFP expression among cell lines (Figure 1E, Table 2).
Infections were performed using multiplicity of infec-
tions (MOIs) 0.3 and MOI 0.6. An almost perfect corre-
lation (R
2 = 0.96) between the infectivity index obtained
in the two conditions was observed with the higher
MOI consistently yielding a 2-fold higher intensity
(Figure 1F). This suggests that concentrations of virus
used to test cellular permissivity were within a flexible
dynamic range. Since results obtained with the two dif-
ferent MOIs were almost identical, the subsequent dis-
cussion will be focused on MOI 0.6 data even though
same conclusions could be drawn using the other MOI.
Moreover, a good correlation (R
2 = 0.66) was observed
between GFP protein and RNA levels (Figure 2C) which
was more significant when two outlier leukemia cell
lines (HL-60 and MOLT4) completely resistant to infec-
tion were removed from the analysis (R
2 = 0.75).
GFP protein expression data were ranked among the
74 cell lines according to infectivity index (Figure 2A).
Six out of 6 cancer cell lines of haematopoetic deriva-
tion were completely resistant to GLV-1h68 infections.
The permissivity to GLV-1h68 based on GFP intensity
was not affected by cells size. In fact, cells with similar
Figure 1 Correlation of GFP gene expression with viral transcription, viral copy number and protein expression in cell lines infected
with GLV-1h68. A) HT-29 and GI-101A cells infected with GLV-1h68 at different time points and hybridized to a customized whole genome
Vaccinia Virus chip; B, C) Screening by RT-PCR of GFP, IMV and Interf proteins in 46 cell lines infected with GLV-1h68. D) Plaque forming assay of
A375, DU-145 and A549 cell lines infected with GLV-1h68 for 8, 20 and 36 hours. E) FACS analysis of GFP expression in 74 cell lines (figure
showed only 3 of them) after infection of with GLV-1h68. Infections with GLV-1h68 were performed using multiplicity of infections (MOI) 0.3 and
MOI 0.6; an almost perfect correlation (R
2 = 0.96) between the infectivity index obtained in the two conditions (F).
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Page 6 of 14size such as SK-MEL-2, and SK-MEL-5 (both very large)
or A375 and M14 (both very small), showed different
permissivity to viral infection. Moreover, permissivity to
GLV-1h68 replication was not tissue-specific nor
patient-specific as three autologous melanoma cell lines
derived from the same progenitor cell clone but from
temporarily distant metastases (Mel-888, MEL 1858 and
MEL 1936) [18] displayed discordant behavior. Side by
side comparison of 1/ΔCt expression levels according to
RT-PCR (Figure 2B) demonstrated a pattern of expres-
sion similar to the infectivity index calculated according
to GFP expression levels.
Detection of cells infected with GFP-carrying vaccinia
provides a fast and sensitive method to measure virus
replication [27] that in our hands correlated well with
transcriptional expression of other VACV genes as well
as the commonly used but more laborious plaque form-
ing assay that yields information about viral particle pro-
duction following cellular infection.
Indexes are similar in other vaccinia strain and Vesicular
Stomatitis Virus infected cells
In order to test whether differential replication of GLV-
1h68 in various cell line is virus-specific, 6 cell lines
were infected in parallel with GLV-1h68 or a different
Vaccinia strain (VACV-WR) and 4 cell lines with GLV-
1h68 or Vesicular Stomatitis Virus (VSV) [21], both
expressing the GFP gene. Twenty hours after infection,
infectivity index was calculated (Additional File 1A)
revealing a good correlation in cell-specific infectivity
driven by the three viruses (R
2 =0 . 8 4a n dR
2 =0 . 8 7 ,
comparing GLV-1h68 to VACV-WR or VSV respec-
tively) suggesting that a common cancer cell phenotype
may influence the replication of these viruses.
Usage of specific cell culture media does not affect
permissivity to GLV-1h68 infections
S i n c et h em a i ns t u d yw a sp e rformed in standardized
conditions using identical but arbitrarily selected culture
media for all cell lines, we tested whether the usage of
different cell cultured media could have impact on cells
permissivity to GLV-1 h 68 infections. A549, HT29,
Panc1 and NCI-H1299 cell lines (showing high, inter-
mediate and low GFP by FACS analysis) were simulta-
neously cultured in cell specific culture media (as
originally recommended by the providing sources) and
infected with GLV-1h68. Twenty hours after infection
cells were collected and viral titers were extrapolated in
a plaque assay using TK-cell lines.
NCI-H1299 and Panc 1 showed lowest permissivity to
VACV compared to HT-29 and A549. These
Table 2 74 cell lines ordered based on the protein level
of Ruc-GFP derived by FACS Data (infectivity index)
Cell line Ruc-GFP
Index
1/Δ
Ct
Cell line Ruc-GFP
Index
1/Δ
Ct
*MOLT4 242.25 0.05 SNB75 22849.59 0.114
*HL-60 890.01 0.038 OVCAR-3 p42 26919.33 0.102
*CCRF-
CEM
890.69 0.095 MDA-MB231
p41
30471.13 #
*K562 1185.59 0.066 OVCAR-8 31066.5 0.142
*SW-620 1223.86 # ACHN 31639.56 #
*SR 1389.99 0.079 RXF-393 35969.66 0.095
*NCI-H522 1723.7 0.081 EKVX 36117.84 0.111
*OVCAR5 1961.62 # A498 36486.43 #
*HCT15 2121.68 0.104 Huh 7.5.1 39321.66 0.116
*LOX-IMVI 2591.66 # NCI-H23 40056.95 #
T47D 2831.5 0.093 PC3 p35 40124.72 #
NCI-H1299 3499.99 # SF539 46092.96 #
RPMI-8226 3891.89 0.085 NCI-ADR_RES 46569.81 0.138
HOP92 4430.72 # TK-10 49256.78 0.136
UO-31 5960.36 # SN12C 50505.78 0.175
A375 6049.59 0.094 MCF-7 55230.93 0.119
HCC2998 6537.28 0.093 SF 295 56037.99 #
786-0 7141.29 0.094 888-MEL 56437.28 0.131
MDA-MB
231
7500.93 # DU-145 56733.35 0.15
Panc1 7876.6 # KM12 57112.82 0.144
SK-Mel 5 7917.7 0.089 PC3 p7 57919.09 0.118
SF268 8703.17 # NCI-H322M 69687.9 0.229
NCI-H460 9247.41 0.097 Siha 72182.24 #
UACC 62 10437.13 0.092 SK-OV-3 73220.28 0.129
U-251 11245.39 # SK-MEL2 75407.23 0.133
NCI-H226 12182.98 0.108 HT29 p155 84833.55 #
Hs578T 13912.24 # M14 94724.62 0.171
GI-101A 14791.4 # *Colo 205 101576.11 0.142
UACC 257 15405.44 0.105 *OVCAR-4 111530.36 0.141
Caki I 15869.9 0.102 *1858-MEL 129262.97 0.164
SK-Mel 28 16737.85 0.097 *397-MEL 134615.99 0.139
MIA PaCa2 17376.47 # *IGR-OVI I 141059.48 0.147
HOP62 19768.46 0.126 *HT29 p6 159709.89 #
MDA-
MB435
20698.92 # *HCT 116 406258.9 0.141
1936-MEL 21079.94 # *A549 p120
avg
409912.11 0.25
SNB19 21349.31 # *OVCAR-3 p7 425559.88 #
BT549 22182.84 0.113 *A549 p4 425962.87 #
To test the correlation between protein and mRNA levels, expression of Ruc-
GFP was screened by RT-PCR in 46 cell lines post-infected. RT-PCR values are
expressed as 1/ΔCt (Ct GFP-Ct 18S). Cells further used in microarray class
comparison and class prediction analysis are indicated with *.
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analysis and ruled out variation in permissivity to
VACV infection due to cell culture conditions (Addi-
tional File 1B).
Transcriptional profiles do not differ among cancer cell
lines with different permissiveness to GLV-1h68
In order to identify correlates of permissivity to viral
infection mediated by GLV-1h68, we performed tran-
scriptional profiles of 74 cancer cell lines prior infection.
The 74 mycoplasma-free cell lines used in this study
were cultured in identical conditions and subjected for
gene expression profiling analysis using 36 K oligo
human array. The complete dataset, was filtered (80%
gene presence across all experiments) to enrich for
informative transcripts obtaining a total of 32,863
transcripts.
Student’stt e s t( c u to f fp 2 value ≤ 0.01) applied to the
filtered data set was used to compare the 10 most to the
10 least permissive cell lines based on infectivity index
(Table 2). This analysis identified 371 genes differentially
expressed between the two groups (global permutation p
value = 0.01). Among them, 117 were up regulated and
254 down regulated in cell lines with higher permissivity
to GLV-1h68 (Table 3). Supervised clustering according
to degree of GFP expression (Figure 2D) did not demon-
strate a gradual change in transcription of the same
genes when the independent intermediate data set was
analyzed although the two classes used for class compari-
son (red bars over the heat map) clearly demonstrated a
different pattern. Thus, this gene selection cannot be
considered independently predictive of permissivity.
Nevertheless, three genes: Growth Differentiation Fac-
tor 15 (GDF-15), CD9 and Integrin B5 (ITGB5), known
Figure 2 Expression of GFP in 74 cell lines infected with GLV-1h68.A )G F Pp r o t e i ne x p r e s s i o nd a t a ,r a n k e da m o n gt h e7 4c e l ll i n e s
according to infectivity index. With * are indicated the 46 cells previously analyzed by RT-PCR. B) Side by side comparison of 1/ΔCt (1/Ct GFP -
Ct 18S) levels obtained by RT-PCR with GFP expression levels obtained by FACS showed similar pattern which is also highlighted by the scatter
plot comparing GFP protein and RNA levels (R
2 = 0.66) (C). D) Heat map of the 371 genes, identified by Student’s t test (p 0.01) comparing 10
highest and 10 lowest GLV 1h68 permissive cell lines. The cells used for the comparison are indicated with a red bar.
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Page 8 of 14Table 3 List of genes down-regulated (on the top) and up-regulated (on the bottom) in cells more permissive to GLV-
1h68 infection
Gene Fc Gene Fc Gene Fc Gene Fc Gene Fc
LCP1 0.18 NIPSNAP3B 0.56 FBXO4 0.63 POLD3 0.68 CEP250 0.76
TMEM194A 0.32 NKTR 0.56 KHDRBS1 0.64 GABPB1 0.68 THAP1 0.76
CORO1A 0.38 RASSF1 0.56 LOC645691 0.64 HIF3A 0.68 SFRS2IP 0.77
NUCB2 0.38 ZNF189 0.56 PGM2 0.64 MBTD1 0.68 TMCO6 0.77
ARHGAP4 0.38 ZNF33B 0.56 SGOL1 0.64 SLC38A1 0.68 ARMC8 0.77
CDCA7L 0.4 CCR2 0.56 CRAMP1L 0.64 THYN1 0.69 TRAPPC6B 0.77
40792 0.43 STAU2 0.56 ARHGAP19 0.64 SLC2A14 0.69 NSA2 0.78
ACADM 0.45 MDN1 0.56 TJAP1 0.64 BIRC6 0.69 FAU 0.78
LOC100289152 0.46 EIF4B 0.56 C14orf126 0.64 GMEB1 0.69 RBBP6 0.78
DNAH11 0.47 ZFP90 0.57 TMEM18 0.64 UBE4A 0.69 UBE2V2 0.78
FBXO5 0.47 EXOSC8 0.57 DAXX 0.64 CCDC77 0.69 VCPIP1 0.79
NCRNA00201 0.48 H2AFV 0.57 TUBB 0.64 KIAA0528 0.7 EPHX3 0.79
NIPSNAP3A 0.48 CCAR1 0.57 RPS25 0.64 ZNRD1 0.7 IFIH1 0.79
FKBP5 0.48 SMARCC1 0.57 BTAF1 0.64 TUT1 0.7 DIP2A 0.79
TP53BP2 0.48 C9orf40 0.57 CHD7 0.64 PRPF4B 0.7 UBA6 0.79
HNRNPCL1 0.48 Q6ZNC3_HUMAN 0.58 MRE11A 0.64 ANKHD1 0.7 CYP2A7 0.79
BARD1 0.49 JHDM1D 0.58 DEDD 0.64 HHEX 0.7 RAD17 0.8
ASF1A 0.49 LOC100129434 0.58 RPS10 0.65 ZNF493 0.7 ANP32E 0.8
LOC100289152 0.49 VWA5A 0.58 MORN3 0.65 AGTR2 0.7 MRPL28 0.81
KDELC2 0.5 CASP3 0.59 PCDH12 0.65 C14orf118 0.7 LOC284080 0.81
UHRF1 0.5 CBL 0.59 RPS25 0.65 SLMO1 0.7 TRIM52 0.81
NDC80 0.5 N4BP2L2 0.59 RAB11FIP1 0.65 PPIL3 0.7 C21orf45 0.81
KIF2A 0.51 CLK1 0.59 ELMOD3 0.66 C14orf135 0.7 SF4 0.81
FUBP1 0.51 HMGN1 0.59 DPY19L2P2 0.66 WFIKKN1 0.7 BAT2L2 0.82
SRPK1 0.51 CEP110 0.59 LARS2 0.66 BAZ1B 0.71 ZNF646 0.82
FAM111A 0.51 TIA1 0.6 LMBRD2 0.66 SMAD1 0.72 LOC643763 0.82
HNRNPA1 0.52 PHIP 0.6 RAF1 0.66 MRPS25 0.72 ZNF665 0.82
PNN 0.52 RAD51AP1 0.6 PTGES3 0.66 SFRS2IP 0.72 TNFAIP8L2 0.82
CENPK 0.52 PHF3 0.6 ATF7IP 0.66 SFRS3 0.72 LRDD 0.82
TRMT5 0.52 CRY1 0.6 OR1J1 0.66 MIS12 0.72 AKAP2 0.83
POLR2A 0.52 LOC729348 0.6 NIPBL 0.66 PCSK7 0.73 ZNF451 0.83
MSL2 0.52 TBP 0.6 KCTD4 0.66 CASC3 0.73 CAPN11 0.83
BAZ1A 0.53 MLL 0.61 LOC729687 0.66 DOK1 0.73 SCXA 0.83
PRDM10 0.53 TMEM44 0.61 DBF4 0.66 XPO6 0.73 CNO 0.83
RPSAP58 0.53 SFRS12 0.61 MSH3 0.66 RPL19 0.73 ZNF691 0.84
HNRNPA2B1 0.54 SFRS13A 0.61 NUP153 0.66 RALA 0.73 SDAD1 0.84
HNRPDL 0.54 FYTTD1 0.61 DNAH11 0.67 FAU 0.74 LOC284513 0.85
TMPRSS3 0.54 KIF11 0.61 MTA2 0.67 SAFB2 0.74 ANKRD49 0.85
SIKE1 0.54 APPL1 0.62 RBM15 0.67 TRIM77 0.74 TAF3 0.85
POLM 0.54 C7orf68 0.62 USE1 0.67 MTMR15 0.74 GTF2H3 0.86
ZNF295 0.55 PHF10 0.62 RBMXL1 0.67 CNOT8 0.74 GLYR1 0.86
TSPYL4 0.55 LOC728643 0.62 ANP32B 0.67 ANKRD62 0.74 EFR3A 0.86
GUSBP1 0.55 CTDSPL2 0.62 BCL11A 0.67 FUBP1 0.74 LOC100131107 0.87
SFPQ 0.55 LOC729348 0.62 WHSC1 0.67 PPWD1 0.75 ATXN7L2 0.87
LRRCC1 0.55 AGAP5 0.63 MOBKL2A 0.67 IL18R1 0.75 TDG 0.87
RIF1 0.55 SDHAP2 0.63 PRKDC 0.68 SDHAF2 0.75 LOC400406 0.88
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Page 9 of 14to play an important role in cell movement and adhe-
sion, ranked at the top of those up-regulated in permis-
sive cell lines (Table 3).
In addition, genes involved in IRF (Interferon Regula-
tory Factor) activation by cytosolic pattern recognition
receptors and in RNA polymerase II activation complex,
were found to be down regulated in permissive cell
lines. Those genes included Interferon Induced with
Helicase C domain 1 (IFIHI), RNA Polymerase II (POL
II), and Reticuloendotheliosis viral oncogen homolog (v-
REL) which are also involved in Interleukin 12 (IL-12)
signaling and macrophage activation (Table 3).
The same 371 genes served as a platform to generate a
heat map based on archival NCI-60 cell lines (59 out of
the 74 cell lines considered in our study) transcriptional
data derived from Genomics and bioinformatics groups,
LMP, CCR, National Cancer Institute, Bethesda, MD
(http://discover.nci.nih.gov/cellminer/loadDownload.do.
This independent dataset demonstrated a comparable
pattern of gene expression (Figure 3A, B). Thus, it is
likely that the transcriptional profiling obtained in our
cell lines is representative and confirmatory of the tran-
scriptional profile of NCI-60 panel cell lines obtained in
other experimental conditions. Based on the 317 differ-
entially expressed genes with functional annotations,
Ingenuity Pathways Analysis (IPA) constructed a pri-
mary network centered on NF-kB signaling (Figure 3C)
and a second ranking network centered on TGF-b and
Interferon-a/b signaling (Figure 3D). In either case, the
majority of transcripts were down-regulated in permis-
sive cell lines as it could have been predicted in teleolo-
gical terms. In fact, expression of v-REL, IFIHI and POL
II and other genes involved in IRF 3/7 signaling and
activation of innate immunity were down-regulated in
Table 3 List of genes down-regulated (on the top) and up-regulated (on the bottom) in cells more permissive to GLV-
1h68 infection (Continued)
HSF1 0.55 XP_942858.1 0.63 PDSS1 0.68 BRAP 0.75 EDA 0.89
CPSF6 0.55 ZRANB2 0.63 CDC40 0.68 FBXO33 0.75 RXRG 0.89
LOC100289563 0.55 OPA1 0.63 LOC646864 0.68 HLTF 0.75 IL17RE 0.89
ZNF117 0.55 GUSB 0.63 ACTR2 0.68 NXF1 0.76 IBSP 0.9
ZNF91 0.56 REL 0.63 DMTF1 0.68 UGT2B15 0.76
GDF15 9.12 ASAH1 2.09 ART3 1.53 POLR2F 1.22 SOX30 1.13
SYTL2 5.05 B4GALT5 2.05 XP_930957.1 1.51 FAM65C 1.22 ERMAP 1.12
NPAS2 3.97 TSPAN3 2.02 PHPT1 1.51 SSX3 1.22 DHRS7B 1.12
ITGB5 3.89 RNF182 1.95 COX6A1 1.49 SYNM 1.22 CAMKK1 1.12
CPM 3.53 MTFMT 1.95 PHLDA3 1.48 HSF4 1.21 LY6G5C 1.11
DUSP4 3.25 OPN1MW2 1.9 SORT1 1.46 SNORD83A 1.21 KIAA1310 1.11
CD9 3.21 LGI3 1.9 ACADS 1.46 RPL10A 1.2 KRTAP10-8 1.09
KIFC3 3.15 BMPR1B 1.84 LOC158434 1.46 GLT8D2 1.2 OR5R1 1.09
UGT2B28 2.86 C2orf82 1.8 SSU72 1.42 DNAH8 1.18 CACNA1F 1.15
ABCB6 2.83 PSMD8 1.78 AGPAT2 1.4 SLC6A8 1.18 AKT2 1.14
GPRC5B 2.82 TIMM50 1.71 KANK2 1.38 LOC100130472 1.17 ZFYVE20 1.14
BAIAP2L1 2.72 GABBR1 1.7 FN1 1.37 CCK 1.17 MOCS1 1.13
CLDN9 2.59 SYAP1 1.7 ERICH1 1.37 GPR113 1.16 SOX30 1.13
FTHL3 2.58 MRPS12 1.69 LDB3 1.37 EFHA2 1.16 ERMAP 1.12
FTH1 2.49 HOXA1 1.62 TPPP 1.36 PDE4C 1.16 DHRS7B 1.12
IGSF3 2.48 PSMD8 1.62 MCF2L 1.36 PTK2 1.15 CAMKK1 1.12
FTH1 2.41 PRDM13 1.61 C19orf63 1.35 POM121L1P 1.15 LY6G5C 1.11
MRAP2 2.37 TMEM147 1.6 MAGEB17 1.35 VSIG1 1.15 KIAA1310 1.11
GABRA1 2.31 GPI 1.59 ELF3 1.32 NEDD9 1.15 KRTAP10-8 1.09
HOXB7 2.22 RNF113A 1.59 ERMP1 1.31 PGPEP1 1.15 OR5R1 1.09
TSKU 2.15 USP3 1.57 WBSCR17 1.3 CACNA1F 1.15
C10orf125 2.14 LOC730144 1.57 GBA2 1.3 AKT2 1.14
AVPI1 2.13 ENTPD6 1.56 CCDC27 1.25 ZFYVE20 1.14
PYGB 2.09 PHLDA3 1.53 DENND5B 1.25 MOCS1 1.13
Gene were ordered based on Fold change (Fc)
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Page 10 of 14permissive cell lines while few transcripts that were up
regulated such as GDF-15 had known inhibitory effects
on innate immune function. Similarly, the canonical
pathway related to assembly of the RNA polymerase II
complex was predominantly down-regulated in permis-
sive cell lines (Figure 3E). Several other statistical
approaches to identify predictors of permissivity yielded
similar results.
Conclusions
The Ruc-GFP carrying vaccinia virus strain GLV-1h68 is
a leading candidate for oncolytic therapy [27].
Based on GFP expression, we observed that permissiv-
ity to VACV infection during the first 20 hours is het-
erogeneous among cell lines but highly reproducible
within each cell line. The tissue origin of each cell line
does not influence the permissivity to infection with the
exception of B cell derivation. Moreover, permissivity
correlates between two VACV constructs and between
them and VSV suggesting that a common cancer cell
phenotype may influence the replication of these viruses.
Transcriptional profiling did not identify clear corre-
lates of permissivity contrary to the experience of others
in different viral systems: for instance, transcriptional
profiling proved useful in the identification of platelet-
derived growth factor receptor as a receptor of adeno-
associated virus type 5 (AAV5) cell entry [28]. In parti-
cular, expression profiling of ovarian cancer cell lines
resistant or susceptible to viral oncolysis, suggested that
the epithelial phenotype of ovarian cancer represents a
Figure 3 Heat map based on genes derived from Student T test (p < 0.01) between permissive and not permissive cell lines using in
house database and external database. A, B) Heat maps based on 371 genes derived from Student’s T test: comparison between the heat
map obtained using our dataset (A) and an independent dataset derived from Genomics and bioinformatics groups, LMP, CCR, National Cancer
Institute, Bethesda, MD (B). IPA based on the 317 differentially expressed genes (derived from Student’s T test p < 0.01) with functional
annotations, constructed a primary network centered on NF-KB signaling (C) and a second ranking network centered on TGF-b and Interferon-a/
b signaling (D) where genes up-regulated or down-regulated in higher permissive cell lines are respectively indicated in red and green. E) A
canonical pathway analysis related to assembly of the RNA polymerase II complex also showed a down-regulation of this pathway in higher
permissive cell lines.
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Page 11 of 14barrier to infection by adenoviruses [29]. Accessibility to
viral receptors was critically linked to the depolarization
and the loss of tight and adherence junctions both hall-
marks of Epithelial-to-Mesenchymal Transition (EMT)
as showed by higher expression of adherens proteins (E-
cadherin), tight junction (occludine) and epithelial mar-
ker (EPCAM) in resistant cells. Conversely, susceptible
cells predominantly expressed markers that are charac-
teristic for mesenchymal cells (vimentin, collagen IV
and N-cadherin). Furthermore, expressions of CD44,
considered a marker of mesenchymal stem cells, and
p120 catenin, were found to be higher in more permis-
sive cell lines. This difference, apparently explains why
oncolytic virotherapy works well in xenograft models
but very poorly in patients because the tight junctions
of epithelial cells shield the adenovirus receptor. When
primary tumors are cultured, apparently only the cells
with some mesenchymal characteristics reproduce in
culture and then tend to further progress through the
EMT.
Interestingly, our results showed a similar behaviour
for VACV infection confirming that ovarian cell lines
less permissive to VACV infection expressed higher
level of mesenchymal molecules and lower expression of
adherens and tight junction proteins (Additional File
2C). However this phenomena was not observed in can-
cer cell lines derived from other tissues suggesting that
this observation is specific to ovarian cancer and cannot
be generalized (Additional File 2A, B).
Class comparison between high and low permissivity
cell lines identified over expression of integrins and tet-
raspanins involved in cellular mobility and adhesion
such as ITGB5 and CD9 in highly permissive cell lines.
The association between integrins and tetraspanins is
common within cells [30] and it has been implicated in
adenoviral replication and internalization [31,32] allow-
ing Adenoviral replication even in cell lines lacking ade-
novirus receptor [33]. CD9 has been also linked to
replication of feline immunodeficiency virus [34] and
canine distemper virus infections [35]. Thus, it is possi-
ble that these two molecules may play a general facilita-
tor role in viral infection for different viruses including
VACV and VSV.
In contrast to the upregulation of integrins and tetra-
spanins, highly permissive cell lines demonstrated con-
stitutive suppression of endogenous innate immune
mechanisms regulated around IRF, NF-kB and Inter-
feron (IFN) signaling as reveled by upregulation of
GDF-15 (also known as Macrophage Inhibitory Factor I-
MIC1) and down regulation of v-REL, IFIHI and POL II
and other genes involved in IRF3/7 dependent signaling
and IL-12 production by macrophages [36]. The down
regulation of the expression of c-Rel, IFIHI and POL2R
observed in VACV higher permissive cell lines supports
ar o l ep l a y e db yt h eh o s t ’s immune response in limiting
vaccinia virus replication, and consequently the effec-
tiveness of oncolytic therapy. Endogenous activation of
innate immunity, in cancer cells appears to hamper viral
replication in other viral models [19] suggesting that
this may be a potential cancer-specific mechanism mod-
ulating the effectiveness of oncolytic therapy.
Although this analysis provided some potentially use-
ful insights about potential factors relevant to VACV
and VSV replication in cancer cells, the signatures iden-
tified could not predict intermediate cancer cells
behavior.
We, therefore, conclude that transcriptional profiling
is unlikely to provide conclusive information about cell
lines permissivity to VACV inf e c t i o ne v e nw h e nt i g h t l y
controlled experimental conditions are applied. Perhaps
higher resolution genomics, functional genomics, epige-
netics or protein based techniques may be required for
identification of such factors. Nevertheless, the informa-
tion obtained here may contribute a road map for the
interpretation of future studies in which a multi-modal-
ity approach will be adopted to address the question of
cancer cell lines permissivity to infection.
Additional material
Additional file 1: Permissivity of cells lines infected with differential
vaccinia strains or with VSV virus and cultured in appropriate cell
culture media. A) Higher and less permissive cell lines infected in
parallel with GLV-1h68 or VACV-WR and with GLV-1h68 or VSV. After
infection, GFP expression was evaluated by FACS analysis.B) Plaque
forming assay of Panc1, NCI-H1299, HT-29 and A549 cell lines cultured in
cell specific culture media and infected with GLV-1h68 for 20 hrs.
Additional file 2: Expression hallmarks of Epithelial-to-
Mesenchymal-Transition (EMT). A) Gene expression of adherens and
tight junction transcripts (light blue) and mesenchymal transcripts
(purple) occurring in lowest permissive cell lines (n = 20) and highest
permissive cell lines (n = 20). Data were based on microarray value. B, C)
Self organization of adherens-tight junction (light blue) and
mesenchymal transcripts (purple) in 74 cells lines (A) and in ovarian
cancer cell lines (B) prior VACV infection. Cells were ranked according
infectivity index.
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